Smith & Nephew is a global medical technology company that specializes in developing, manufacturing, marketing, and selling medical devices and services. The company operates in various segments including Orthopedics, Sports Medicine, Ear, Nose, and Throat, as well as Advanced Wound Management. Despite its strong presence in the market and dominant global market position, Smith & Nephew has failed to generate shareholder value in recent years due to various operational challenges.
While Smith & Nephew has an impressive global market position and strong brand perception, its profitability profile is concerning. The company generated $5.55 billion in revenue in 2023, with Orthopedics contributing 40%, Sports Medicine contributing 31%, and Wound contributing 29%. However, the profitability margins differ significantly among these segments, with Orthopedics having operating margins of only 11%, compared to 22% for Sports Medicine and Wound. The declining operating margins in the Orthopedics segment have been a major factor in the company’s failure to create value for shareholders.
One of the primary reasons for the declining operating margins in the Orthopedics segment is self-inflicted issues related to supply chain management, logistics, and manufacturing. These issues have led to back orders and delays in delivering the required implants and tools for procedures. Additionally, the company has experienced a significant amount of management turnover over the past five years, which has further exacerbated its operational challenges. Without a stable management team to implement long-term strategies, it is difficult for the company to address its operational issues effectively.
Cevian Capital, an international investment firm, has acquired a 5.11% ownership stake in Smith & Nephew with the intention of enhancing the company’s long-term value through active ownership. As a “constructive activist,” Cevian aims to help the company improve its operating performance and regain momentum in the market. With a focus on long-term investments and operational improvements, Cevian is well-positioned to assist Smith & Nephew in addressing its challenges and unlocking potential upside.
Smith & Nephew’s management has released a 12-point plan to address its operational issues, with a major focus on fixing the Orthopedics segment. While this is a step in the right direction, sustained operational improvements will require a long-term mindset and stability in leadership. Cevian’s experience in helping companies improve their operations makes it a suitable partner for Smith & Nephew in implementing these strategies. By working closely with the company at the board level, Cevian can provide valuable insights and guidance to drive operational enhancements and boost profitability.
Overall, Smith & Nephew’s partnership with Cevian Capital presents an opportunity for the company to revitalize its business and deliver long-term value to shareholders. With a focus on operational excellence and a commitment to long-term success, Smith & Nephew has the potential to regain its market leadership and drive sustainable growth in the medical technology industry.